Role of platelet-rich plasma in pelvic floor disorders: A systematic review


Background: Management for pelvic floor disorders needs to be improved. Plateletrich plasma (PRP) offers an innovative treatment in general medical care to promote cell regeneration.

Objective: This review aims to investigate the role of PRP in pelvic floor disorders.

Materials and Methods: 6 international databases were accessed using several keywords namely PubMed, Science Direct, Cochrane Library, ProQuest, Google Scholar, and Scopus. The inclusion criteria were articles written in English, published in 10-yr period from 2012 until 2022, and investigated the relevant topic. This systematic review followed PRISMA guideline.

Results: 644 articles were found in several databases and 15 articles met the criteria. Management for pelvic floor disorders needs to be improved, but there are still many challenges, such as less effective treatments, risk of recurrence, and postoperative wound healing. PRP offers an innovative treatment in general medical care to promote cell regeneration. A total of 644 articles from the database were found, but 15 studies met the criteria. A total of 600 women with various pelvic floor disorders treated with PRP were analyzed. PRP positively impacts female sexual dysfunction, perineal trauma, vulvovaginal atrophy, stress urinary incontinence, vesicovaginal fistula, perineal rupture, and pelvic organ prolapse. Dosages, preparation techniques, injection techniques, and additive materials are varied. Most studies do not report side effects from the therapy, but the urinary disorder complaints must be paid attention to.

Conclusion: PRP can be used to manage pelvic floor disorders. Future studies should clarify and standardize the dose in each case and how to make PRP produce the best results.

Key words: Platelet-rich plasma, Pelvic floor disorders, Women.

[1] Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300: 1311–1316.

[2] Hallock JL, Handa VL. The epidemiology of pelvic floor disorders and childbirth: An update. Obstet Gynecol Clin North Am 2016; 43: 1–13.

[3] Fontenele MQS, Moreira MA, de Moura ACR, de Figueiredo VB, Driusso P, Nascimento SL. Pelvic floor dysfunction distress is correlated with quality of life, but not with muscle function. Arch Gynecol Obstet 2021; 303: 143–149.

[4] Hong M-K, Ding D-Ch. Current treatments for female pelvic floor dysfunctions. Gynecol Minim Invasive Ther 2019; 8: 143–148.

[5] Umoh UE, Arya LA. Surgery in urogynecology. Minerva Med 2012; 103: 23–36.

[6] Zambon JP, Batezini NSS, Pinto ERS, Skaff M, Girotti ME, Almedia FG. Do we need new surgical techniques to repair vesico-vaginal fistulas? Int Urogynecol J 2010; 21: 337–342.

[7] Parker-Autry CY, Barber MD, Kenton K, Richter HE. Measuring outcomes in urogynecological surgery: “Perspective is everything”. Int Urogynecol J 2013; 24: 15–25.

[8] Parker-Autry CY, Markland AD, Ballard AC, Downs- Gunn D, Richter HE. Vitamin D status in women with pelvic floor disorder symptoms. Int Urogynecol J 2012; 23: 1699–1705.

[9] Gyang A, Hartman M, Lamvu G. Musculoskeletal causes of chronic pelvic pain: What a gynecologist should know. Obstet Gynecol 2013; 121: 645–650.

[10] Morrison P. Musculoskeletal conditions related to pelvic floor muscle overactivity. In: Padoa A, Rosenbaum TY. The overactive pelvic floor. Cham: Springer; 2016.

[11] Alsousou J, Ali A, Willett K, Harrison P. The role of platelet-rich plasma in tissue regeneration. Platelets 2013; 24: 173–182.

[12] Sanoulis V, Nikolettos N, Vlahos N. The use of platelet-rich plasma in the gynaecological clinical setting. A review. Hell J Obstet Gynecol 2019; 18: 55–65.

[13] The Joanna Briggs Institute. Checklist for quasi-experimental studies. Available at: http://joannabriggs. org/assets/docs/critical-appraisal-tools/JBI_ Quasi-Experimental_Appraisal_Tool2017.pdf. 2017.

[14] Critical Appraisal Skills Programme (CASP). CASP checklist: Cohort study. Available at: CASP-Cohort-Study-Checklist-2018_fillable_form.pdf. 2018.

[15] Long HA, French DP, Brooks JM. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Methods Med Health Sci 2020; 1: 31–42.

[16] Chiang Ch-H, Kuo H-Ch. The efficacy and mid-term durability of urethral sphincter injections of platelet-rich plasma in treatment of female stress urinary incontinence. Front Pharmacol 2022; 13: 847520.

[17] Kabakci AG, Bozkir MG. Effectiveness of platelet-rich plasma treatment in perineal trauma: A case report. Clin Exp Obstet Gynecol 2021; 48: 728–732.

[18] Jiang Y-H, Lee P-J, Kuo H-C. Therapeutic efficacy of urethral sphincter injections of platelet-rich plasma for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency: A proof-of-concept clinical trial. Int Neurourol J 2021; 25: 51–58.

[19] Sukgen G, Kaya AE, Karagun E, Calskan E. Platelet-rich plasma administration to the lower anterior vaginal wall to improve female sexuality satisfaction. Turk J Obstet Gynecol 2019; 16: 228–234.

[20] Behnia-Willison F, Nguyen TTT, Norbury AJ, Mohamadi B, Salvatore S, Lam A. Promising impact of platelet rich plasma and carbon dioxide laser for stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol X 2019; 5: 100099.

[21] Hassan Soliman HEMAA. Analysis of the post-partum vaginal repair by injecting platelet-rich plasma; a study undertaken in Saudi German hospital KSA. J World’s Poult Res 2019; 9: 122–125.

[22] Gaber MA, Shaltout ShA. Assessment of autologous platelet-rich plasma as a local therapy for female sexual dysfunction. Menoufia Med J 2021; 34: 61–65.

[23] Hersant B, Sidahmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, et al. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: A phase 2 pilot study. Menopause 2018; 25: 1124–1130.

[24] Daneshpajooh A, Mirzaei M, Farsinejad A, Naghibzadeh-Tahami A, Eslami A. The effect of periurethral injection of pure platelet-rich plasma in the treatment of urinary incontinence in female patients: A randomized clinical trial. J Kerman Univ Med Sci 2021; 28: 330–337.

[25] Gorlero F, Glorio M, Lorenzi P, Bruno-Franco M, Mazzei C. New approach in vaginal prolapse repair: Miniinvasive surgery associated with application of plateletrich fibrin. Int Urogynecol J 2012; 23: 715–722.

[26] Long Ch-Y, Lin K-L, Shen Ch-R, Ker Ch-R, Liu Y-Y, Loo ZX, et al. A pilot study: Effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence. Sci Rep 2021; 11: 1584.

[27] Dardeer HHM, Mohamed ML, Elshahat AM, Mohammed GF, Gadallah AM. Platelet-rich plasma: An effective modality to improve sexuality in FGM/C. Sexologies 2022; 31: 394–402.

[28] Streit-cieckiewicz D, Futyma K, Miotla P, Grzybowska ME, Rechberger T. Platelet-rich plasma as adjuvant therapy for recurrent vesicovaginal fistula: A prospective case series. J Clin Med 2019; 8: 2122.

[29] Aguilar P, Hersant B, SidAhmed-Mezi M, Bosc R, Vidal L, Meningaud JP. Novel technique of vulvo-vaginal rejuvenation by lipofilling and injection of combined platelet-rich-plasma and hyaluronic acid: A case-report. Springerplus 2016; 5: 1184.

[30] Melo I. Platelet rich plasma, in the treatment of sexual disfunction afther pelvic radiotherapy for cancer. Obstet Gynecol Int J 2022; 13: 222–224.

[31] Chrysanthopoulou EL, Pergialiotis V, Perrea D, ?ourkoulis S, Verikokos C, Doumouchtsis SK. Platelet rich plasma as a minimally invasive approach to uterine prolapse. Med Hypotheses 2017; 104: 97–100.

[32] Prodromidou A, Zacharakis D, Athanasiou S, Protopapas A, Michala L, Kathopoulis N, et al. The emerging role on the use of platelet-rich plasma products in the management of urogynaecological disorders. Surg Innov 2022; 29: 80–87.

[33] Nikolopoulos KI, Pergialiotis V, Perrea D, Doumouchtsis SK. Restoration of the pubourethral ligament with platelet rich plasma for the treatment of stress urinary incontinence. Med Hypotheses 2016; 90: 29–31.

[34] Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: A review and author’s perspective. J Cutan Aesthet Surg 2014; 7: 189–197.

[35] Pachito DV, Bagattini AM, de Almeida AM, Mendrone- Junior A, Riera R. Technical procedures for preparation and administration of platelet-rich plasma and related products: A scoping review. Front Cell Dev Biol 2020; 8: 598816.

[36] Dashore Sh, Chouhan K, Nanda S, Sharma A. Preparation of platelet-rich plasma: National IADVL PRP taskforce recommendations. Indian Dermatol Online J 2021; 12: S12–S23.

[37] Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: Molecular mechanisms and therapeutic trajectory. Front Vet Sci 2019; 6: 192.

[38] Jo ChH, Roh YH, Kim JE, Shin S YK. Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation. J Oral Implant 2013; 39: 525–532.

[39] Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermato-endocrinol 2012; 4: 253–258.

[40] Anitua E, Sanchez M, Orive G. The importance of understanding what is platelet-rich growth factor (PRGF) and what is not. J Shoulder Elb Surg 2011; 20: 23–24.